Data Sheet (Cat.No.T2S0501)

TargetMol
A DRUG SCREENING EXPERT

Ilexgenin A

Chemical Properties



CAS No.:	108524-94-3
Formula:	C30H46O6
Molecular Weight:	502.69
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Ilexgenin A is a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis Merr
Targets(IC_{50})	Akt: None AMPK: None Caspase: None ERK: None IkB: None IL Receptor: None LDL: None NF-κB: None NO: None PI3K: None PKC: None ROS: None STAT: None TNF-α: None VEGFR: None
In vitro	Ilexgenin A (IA), a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis Merr.treatment with IA attenuated atherosclerosis in high-fat diet-induced apolipoprotein E deficient mice via a series of effects involving regulation of lipid parameters, decrease of atherosclerosis-related indexes, inhibition of inflammatory cytokines secretion and pathological changes of main organs. The underlying mechanism of IA was investigated on oxidized low-density lipoprotein (Ox-LDL)-induced THP-1 cells. Pre-treatment with IA decreased active inflammation cytokines involving interleukin-6 (IL-6), IL-1 and tumor necrosis factor-α (TNF-α) expression in a concentration-dependent manner.IA inhibited the phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), IKKα phosphorylation and NF-κB activity induced by Ox-LDL. Overall, these findings define IA as a novel drug candidate for anti-atherosclerotic therapy[2].

Solubility Information

Solubility	DMSO: 10 mM (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.989 mL	9.946 mL	19.893 mL
5 mM	0.398 mL	1.989 mL	3.979 mL
10 mM	0.199 mL	0.995 mL	1.989 mL
50 mM	0.04 mL	0.199 mL	0.398 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Inhibition of lipolysis by ilexgenin A via AMPK activation contributes to the prevention of hepatic insulin resistance. Eur J Pharmacol. 2017 Oct 15;813:84-93.

2. Liu C , Zhao J , Liu Y X , et al. A novel pentacyclic triterpenoid, Ilexgenin A, shows reduction of atherosclerosis in apolipoprotein E deficient mice[J]. International Immunopharmacology, 2016, 40:115-124.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481